Symbiosis Pharmaceutical Services

Stirling, United Kingdom
Find alternatives to Symbiosis Pharmaceutical Services for Cell Therapy →
Program data pending ClinicalTrials.gov matching · Last scored 2026-10-29
76.8
Signal Score
✓ FDA Inspections (1) ○ Clinical Trials ○ SEC Filings ○ Press ○ EMA GMP ✓ MHRA GMP (8) ✓ HC GMP (3)

Quick Facts: Symbiosis Pharmaceutical Services

Signal Score
76.8/100 (as of 2026-10-29)
Quality Compliance
100.0/100 — Clean MHRA record: 8 compliant GMP certificates (no deductions)
Headquarters
Stirling, United Kingdom
Modalities
Cell Therapy
Active Programs
No ClinicalTrials.gov matches confirmed
Data Sources
FDA Data Dashboard, ClinicalTrials.gov, SEC EDGAR, press monitoring
Scored By
CDMO Signal — independent CDMO intelligence platform

About Symbiosis Pharmaceutical Services

Pure-play CDMO.

Signal Score & Pillar Breakdown

Quality Compliance 100.0
Clean MHRA record: 8 compliant GMP certificates (no deductions)
Sources: FDA Data Dashboard, MHRA GMDP
Clean MHRA record: 8 compliant GMP certificates (no deductions)
FDA Inspections1 on record
Warning Letters0
Last InspectionNo Action Indicated (NAI) (2025-01-31)
MHRA GMP Certificates8 on record
Most Recent HC OutcomeCompliant · 2025-02-04
HC Attribution3 company-level
Source: Health Canada Drug and Health Product Inspections Database. Ratings shown in Health Canada's own vocabulary; not equivalent to FDA classifications. Company-level records are attributed by the regulator's published establishment name, not by a verified site identifier. Contains information licensed under the Open Government Licence – Canada.
Clean MHRA record: 8 compliant GMP certificates (no deductions)
Operations —
No ClinicalTrials.gov facility matches confirmed for this manufacturer.
Programs — no verified data
Sponsors— no verified data
ModalitiesCell Therapy
No clinical trial matches found for this manufacturer
Operational score requires ClinicalTrials.gov data
Scored from ClinicalTrials.gov and FDA records; SEC EDGAR and press items are shown as company signals, not scored. No unverified estimates shown.
Financial Stability 60.0
Private company
Financial assessment: 60.0/100
Source: company profile (public/private status, parent company)
Profile-based financial assessment
SEC FilingsPrivate company
Private company
Financial assessment: 60.0/100
Capacity 53.0
1 manufacturing site: Stirling, UK
Modalities: Cell Therapy
Capacity assessment: 53.0/100
Sites: Stirling, UK
Source: company profiles (manufacturing sites, modality breadth)
1 manufacturing site
1 manufacturing site: Stirling, UK
Modalities: Cell Therapy
Capacity assessment: 53.0/100

Symbiosis Pharmaceutical Services FDA Inspection History

2025-01
NAI VAI OAI
Date Site Type 483 citations posted Classification
2025-01-31
Symbiosis Pharmaceutical Services Limited
Stirling Facility-linked
Human Cellular, Tissue, and Gene Therapies Not posted No Action Indicated (NAI)
Source: FDA Data Dashboard · Retrieved Nov 21, 2026

Symbiosis Pharmaceutical Services MHRA GMP Compliance 8 certificates

2025-02
2025-02
2025-02
2025-02
2024-08
2024-08
2023-09
2023-09
Compliant Non-Compliant
Certificate Site City / Postcode Inspection Date Status
UK MIA(IMP) 40211 Insp IMP 40211/405290-0019[I] SYMBIOSIS PHARMACEUTICAL SERVICES LIMITED STIRLING FK9 4NF 2025-02-04 COMPLIANT
UK MIA(IMP) 40211 Insp IMP 40211/37423042-0004[I] SYMBIOSIS PHARMACEUTICAL SERVICES LIMITED STIRLING FK9 4TS 2025-02-04 COMPLIANT
UK MIA 40211 Insp GMP 40211/405290-0020[H] SYMBIOSIS PHARMACEUTICAL SERVICES LIMITED STIRLING FK9 4NF 2025-02-04 COMPLIANT
UK MIA 40211 Insp GMP 40211/37423042-0005[H] SYMBIOSIS PHARMACEUTICAL SERVICES LIMITED STIRLING FK9 4TS 2025-02-04 COMPLIANT
UK MIA(IMP) 40211 Insp IMP 40211/33209260-0005[I] SYMBIOSIS PHARMACEUTICAL SERVICES LIMITED STIRLING FK9 4NF 2024-08-20 COMPLIANT
UK MIA 40211 Insp GMP 40211/33209260-0006[H] SYMBIOSIS PHARMACEUTICAL SERVICES LIMITED STIRLING FK9 4NF 2024-08-20 COMPLIANT
UK GMP 40211 Insp GMP/IMP 40211/33209260-0001 [H] SYMBIOSIS PHARMACEUTICAL SERVICES LIMITED STIRLING FK9 4NF 2023-09-08 COMPLIANT
UK GMP 40211 Insp GMP/IMP 40211/33209260-0001 [V] SYMBIOSIS PHARMACEUTICAL SERVICES LIMITED STIRLING FK9 4NF 2023-09-08 COMPLIANT
Source: MHRA GMDP Database · Retrieved Nov 21, 2026

Japan-accredited overseas site (PMDA)

cell and gene therapy (CGT) · 1 site

  • Stirling, United Kingdom · Symbiosis Pharmaceutical Services Limited — cell and gene therapy (CGT) · valid to Nov 7, 2028

PMDA accreditation of a foreign manufacturing site is recognition within Japan's regulatory system, not an inspection outcome. PMDA's list covers only manufacturing sites outside Japan, so a company's plants in Japan are not on it. Source: PMDA, list of accredited/registered foreign manufacturers (as of Oct 16, 2026), Public Data License 1.0 (terms)

Hiring Activity Beta

Built from public job postings when a company's own roles can be read. Job postings are signals, not statements by the company; each one below links to the original. How we collect this
No hiring data yet. We haven't found a public jobs feed for this company.
Source: public careers pages · Checked Nov 20, 2026

Frequently Asked Questions About Symbiosis Pharmaceutical Services

How many FDA inspections does Symbiosis Pharmaceutical Services have on record?
CDMO Signal tracks 1 FDA inspection for Symbiosis Pharmaceutical Services, sourced from the FDA inspection database. See the full inspection history above.
Has Symbiosis Pharmaceutical Services received an FDA warning letter?
CDMO Signal has no FDA warning letters on record for Symbiosis Pharmaceutical Services.
Does Symbiosis Pharmaceutical Services hold EMA or MHRA GMP certificates?
CDMO Signal tracks 8 MHRA GMP certificates for Symbiosis Pharmaceutical Services.
What is Symbiosis Pharmaceutical Services's CDMO Signal Score?
Symbiosis Pharmaceutical Services has a Signal Score of 77/100, based on quality, operations, financial stability, and capacity data.
Evaluating Symbiosis Pharmaceutical Services for a manufacturing program?
Use the free AI matchmaker to compare Symbiosis Pharmaceutical Services against other CDMOs by FDA, EMA, and clinical-trial data — no login required.
Find & compare CDMOs →
Represent this organization? Contact us to verify or update this profile.
See all CDMOs in:
Cell Therapy CDMOs →

Similar CDMOs

eXmoor Pharma
Bristol, United Kingdom
Signal Score: 78.1
Cell Therapy, AAV
HiTech Health
London, United Kingdom
Signal Score: 76.8
Cell Therapy
Rose BioSolutions
Rockville, MD · Memphis, TN · Keele, United Kingdom
Signal Score: 64.0
AAV, Lentiviral, Adenoviral, Plasmid, Cell Therapy, CAR-T
Ori Biotech
London, United Kingdom
Signal Score: 59.0
CAR-T, Cell Therapy
Cell and Gene Therapy Catapult
Stevenage, United Kingdom
Signal Score: 59.0
CAR-T, Cell Therapy, AAV

Compare Symbiosis Pharmaceutical Services with another CDMO

Side-by-side scoring, FDA inspection history, EMA/MHRA GMP coverage, and clinical-program footprint.
Compare side-by-side
See two CDMOs' scoring, inspection history, and clinical footprint next to each other.
Open comparison →
Run a sourcing search
Describe your program's requirements — Signal matches CDMOs against FDA, EMA/MHRA, ClinicalTrials.gov and capacity signals.
Search for a CDMO →
Get updates on Symbiosis Pharmaceutical Services
Get an email when a CDMO on this list has a new FDA inspection, GMP certificate, or scoring change.